Indiana University Health is the first health system in the nation to administer a newly FDA-approved imaging drug designed to help physicians evaluate suspected recurrent brain cancer, marking an important step forward in precision oncology and reinforcing IU Health's commitment to advancing theranostic care for patients.
The first patient at IU Health received Pixclara® (floretyrosine F 18 or 18F-FET), an imaging drug developed by Telix Pharmaceuticals and now approved for use in adults and children with possible recurrence of glioma, a type of brain tumor diagnosed in thousands of Americans each year.